SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Xu Weiping)
 

Search: WFRF:(Xu Weiping) > Plasma concentratio...

  • Forsman, Lina DaviesKarolinska Institutet,Karolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden;Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden (author)

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China : a study protocol of a prospective observational cohort study

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-10-04
  • BMJ,2018
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-371420
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371420URI
  • https://doi.org/10.1136/bmjopen-2018-023899DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:139690764URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-153393URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Swedish Heart Lung Foundation [20150508]; Swedish National Research Council [540-2013-8797]; National Research Foundation of China [81361138019]
  • Individualised treatment through therapeutic drug monitoring (TDM) may improve tuberculosis (TB) treatment outcomes but is not routinely implemented. Prospective clinical studies of drug exposure and minimum inhibitory concentrations (MICs) in multidrug-resistant TB (MDR-TB) are scarce. This translational study aims to characterise the area under the concentration-time curve of individual MDR-TB drugs, divided by the MIC for Mycobacterium tuberculosis isolates, to explore associations with markers of treatment progress and to develop useful strategies for clinical implementation of TDM in MDR-TB.Methods and analysis: Adult patients with pulmonary MDR-TB treated in Xiamen, China, are included. Plasma samples for measure of drug exposure are obtained at 0, 1, 2, 4, 6, 8 and 10 hours after drug intake at week 2 and at 0, 4 and 6 hours during weeks 4 and 8. Sputum samples for evaluating time to culture positivity and MIC determination are collected at days 0, 2 and 7 and at weeks 2, 4, 8 and 12 after treatment initiation. Disease severity are assessed with a clinical scoring tool (TBscore II) and quality of life evaluated using EQ-5D-5L. Drug concentrations of pyrazinamide, ethambutol, levofloxacin, moxifloxacin, cycloserine, prothionamide and para-aminosalicylate are measured by liquid chromatography tandem-mass spectrometry and the levels of amikacin measured by immunoassay. Dried blood spot on filter paper, to facilitate blood sampling for analysis of drug concentrations, is also evaluated. The MICs of the drugs listed above are determined using custom-made broth microdilution plates and MYCOTB plates with Middlebrook 7H9 media. MIC determination of pyrazinamide is performed in BACTEC MGIT 960.Ethics and dissemination: This study has been approved by the ethical review boards of Karolinska Institutet, Sweden and Fudan University, China. Informed written consent is given by participants. The study results will be submitted to a peer-reviewed journal. Trial registration number NCT02816931; Pre-results.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Niward, KatarinaLinköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Region Östergötland, Infektionskliniken i Östergötland(Swepub:liu)katni01 (author)
  • Hu, YiFudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China (author)
  • Zheng, RongrongXiamen City Ctr Dis Control, Dept TB & AIDS Prevent, Xiamen, Peoples R China (author)
  • Zheng, XubinFudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China (author)
  • Ke, RanXiamen City Ctr Dis Control, Dept TB & AIDS Prevent, Xiamen, Peoples R China (author)
  • Cai, WeipingXiamen City Ctr Dis Control, Dept TB & AIDS Prevent, Xiamen, Peoples R China (author)
  • Hong, ChaoXiamen City Ctr Dis Control, Dept TB & AIDS Prevent, Xiamen, Peoples R China (author)
  • Li, YangFudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China (author)
  • Gao, YazhouFudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China (author)
  • Werngren, JimPubl Hlth Agcy Sweden, Dept Microbiol, Stockholm, Sweden (author)
  • Paues, Jakob,1972-Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Region Östergötland, Infektionskliniken i Östergötland(Swepub:liu)jakpa82 (author)
  • Kuhlin, JohannaKarolinska Institutet,Karolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden;Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden (author)
  • Simonsson, Ulrika S H,ProfessorKarolinska Institutet,Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden,Uppsala Univ, Sweden(Swepub:uu)usv12211 (author)
  • Eliasson, ErikKarolinska Institutet,Karolinska Univ Hosp, Div Clin Pharmacol, Dept Lab Med, Stockholm, Sweden (author)
  • Alffenaar, Jan-WillemUniv Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands (author)
  • Mansjo, MikaelPubl Hlth Agcy Sweden, Dept Microbiol, Stockholm, Sweden (author)
  • Hoffner, SvenKarolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden (author)
  • Xu, BiaoFudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China (author)
  • Schön, ThomasLinköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Kalmar Cty Hosp, Sweden(Swepub:liu)thosc49 (author)
  • Bruchfeld, JudithKarolinska Institutet,Karolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden;Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden (author)
  • Karolinska InstitutetKarolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden;Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden (creator_code:org_t)

Related titles

  • In:BMJ Open: BMJ8:92044-6055

Internet link

Find in a library

  • BMJ Open (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view